Oncology Views & Analysis

Views & Analysis

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

Oncology

After 'Year of Harvest', Bayer looks to diversify modalities

Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Hernexeos and what’s next, with Vicky Brown

Day One's big bet on tovorafenib just keeps paying off

Collaboration & personalisation in rare disease R&D, with AO...

Daiichi Sankyo gears up for five ADC launches in 2026

After 'Year of Harvest', Bayer looks to diversify modalities

A cancer treatment modality that prioritises QoL, with Ben Z...

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks